Affy, Decode Defend Utility of Array-Based GWA Studies in Wake of NEJM Critiques

NEJM last week published a quartet of perspectives offering a range of opinions on the value of GWAS and DTC testing, but two critical articles in particular caused financial analysts and the American news media to conclude that the perspectives could negatively impact companies that provide tools for these studies.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.